To evaluate the performance of first trimester combined screening for the detection of rare chromosomal abnormalities. STUDY DESIGN: A database containing 36,254 pregnancies was analyzed. These patients had been recruited at 15 US centers and included singleton pregnancies from 10 3/7 e 13 6/7 weeks. All patients had a nuchal translucency (NT) scan and those without a cystic hygroma (N¼36,120) underwent a combined first trimester screening test ('FTS' -NT, PAPP-A and fbHCG). A risk cut-off of 1:300, which was used for defining high risk of Trisomy 21, was also used to evaluate the detection rate for rare chromosomal abnormalities using the combined FTS test. RESULTS: 36,120 patients underwent combined FTS. Of these, 129 were found to have one of the following chromosomal abnormalities: Trisomy 21, Trisomy 18, Trisomy 13 or Turner syndrome. 42 were found to have 'other' rare chromosomal abnormalities such as triploidy, structural chromosomal abnormalities, sex chromosome abnormalities or unusual chromosomal abnormalities (e.g. 47XX +16), giving an incidence of 1.1 in 1,000 for rare chromosomal abnormalities. Of these 42 pregnancies, only 2 (5%) had an NT measurement of 3mm. The detection rate of combined FTS, using a risk cut-off of 1:300, was 33% (14 of 42 cases). Therefore, 67% of cases of rarer fetal chromosomal abnormalities had a 'normal' combined FTS risk (<1:300) and 95% had a 'normal' NT (<3mm). CONCLUSION: The incidence of rare fetal chromosomal abnormality is very low in a general, unselected obstetric population. Traditional FTS methods are unable to identify the vast majority of rare chromosomal abnormalities. First trimester NT measurement is a very poor stand-alone screening test for rare chromosomal abnormalities (sensitivity of 5%). It has been suggested that the potential detection of rare chromosomal abnormalities justifies the continued use of traditional NT/serum screening as the primary screening offered to pregnant women. Given the superior sensitivity and negative/positive predictive value of NIPT for common chromosome abnormalities, our data suggest that a paradigm shift to NIPT as primary screening methodology should result in overall higher detection rates of aneuploidy with a significant reduction in false positive results, given the lack of value of traditional NT/serum screening for rare chromosome abnormalities. OBJECTIVE: Non-invasive prenatal testing (NIPT) via cell-free fetal DNA is widely implemented in obstetrical care without standardized counseling regarding utility and limitations. The aim of this study is to assess patients' understanding of NIPT. STUDY DESIGN: We conducted a 55-question survey from JulyOctober 2015 at a MFM referral center in a large metropolitan area. Subjects were recruited at the time of their scheduled appointment (before seeing the MFM provider) and queried on demographics and their understanding of NIPT. RESULTS: The survey was completed by 161 subjects, of which 97 (60%) were 35 years or older at their due date. Subjects self-identified as Caucasian (109; 68%), Asian (17; 11%), Hispanic (16; 10%), Black (4; 2%), or mixed (11; 7%). The sampled population is highly educated; 133 (83%) women had a college degree or more.
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888 Cell-free fetal DNA for aneuploidy screening: How much do patients understand? OBJECTIVE: Non-invasive prenatal testing (NIPT) via cell-free fetal DNA is widely implemented in obstetrical care without standardized counseling regarding utility and limitations. The aim of this study is to assess patients' understanding of NIPT. STUDY DESIGN: We conducted a 55-question survey from JulyOctober 2015 at a MFM referral center in a large metropolitan area. Subjects were recruited at the time of their scheduled appointment (before seeing the MFM provider) and queried on demographics and their understanding of NIPT. RESULTS: The survey was completed by 161 subjects, of which 97 (60%) were 35 years or older at their due date. Subjects self-identified as Caucasian (109; 68%), Asian (17; 11%), Hispanic (16; 10%), Black (4; 2%), or mixed (11; 7%). The sampled population is highly educated; 133 (83%) women had a college degree or more.
Thirty-five were 5-20 weeks and 111 were >20 weeks gestational age (15 skipped this question). Eighty (50%) were multiparous and 57 (71%) reported having had NIPT in the last pregnancy. Their understanding of NIPT was derived from: the primary obstetrician (POB) (68%), genetic counselors (23%), internet/media (22%), friends (11%), and other (3%).
All subjects had NIPT drawn by their POB during routine prenatal care, but surprisingly 53 (32%) incorrectly answered that they had not had the test done. Eighty-two (51%) knew that NIPT screened for sex chromosomes, 101 (63%) for Trisomy (T) 21, 75 (47%) for T18, and 58 (36%) for T13, while 39 (24%) reported they did not know the purpose of NIPT. Among those who knew that NIPT screens for T21, 52/101 (51%) reported that NIPT was 95-99% accurate for T21, 79 (78%) said >90% accurate for T21, and 23 (23%) were not sure. Twenty-four (15%) reported desire for invasive testing regardless of results, while 64 (40%) answered that low-risk NIPT was one of the reasons they decided not to have invasive testing.
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